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Abstract
Background: Foot-and-mouth disease (FMD) is endemic in Uganda in spite of the control measures used. Various
aspects of the maintenance and circulation of FMD viruses (FMDV) in Uganda are not well understood; these
include the role of the African buffalo (Syncerus caffer) as a reservoir for FMDV. To better understand the
epidemiology of FMD at the livestock-wildlife-interface, samples were collected from young, unvaccinated cattle
from 24 pastoral herds that closely interact with wildlife around Queen Elizabeth National Park in Uganda, and
analysed for evidence of FMDV infection.
Results: In total, 37 (15 %) of 247 serum samples had detectable antibodies against FMDV non-structural proteins
(NSPs) using a pan-serotypic assay. Within these 37 sera, antibody titres ≥ 80 against the structural proteins of
serotypes O, SAT 1, SAT 2 and SAT 3 were detected by ELISA in 5, 7, 4 and 3 samples, respectively, while
neutralizing antibodies were only detected against serotype O in 3 samples. Two FMDV isolates, with identical VP1
coding sequences, were obtained from probang samples from clinically healthy calves from the same herd and are
serotype SAT 1 (topotype IV (EA-I)). Based on the VP1 coding sequences, these viruses are distinct from previous
cattle and buffalo SAT 1 FMDV isolates obtained from the same area (19–30 % nucleotide difference) and from the
vaccine strain (TAN/155/71) used within Uganda (26 % nucleotide difference). Eight herds had only one or a few
animals with antibodies against FMDV NSPs while six herds had more substantial evidence of prior infection with
FMDV. There was no evidence for exposure to FMDV in the other ten herds.
Conclusions: The two identical SAT 1 FMDV VP1 sequences are distinct from former buffalo and cattle isolates
from the same area, thus, transmission between buffalo and cattle was not demonstrated. These new SAT 1 FMDV
isolates differed significantly from the vaccine strain used to control Ugandan FMD outbreaks, indicating a need for
vaccine matching studies. Only six herds had clear serological evidence for exposure to O and SAT 1 FMDV.
Scattered presence of antibodies against FMDV in other herds may be due to the occasional introduction of
animals to the area or maternal antibodies from past infection and/or vaccination.
The evidence for asymptomatic FMDV infection has implications for disease control strategies in the area since this
obstructs early disease detection that is based on clinical signs in FMDV infected animals.
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Background
Foot-and-mouth disease (FMD) is a highly contagious
viral disease affecting a wide range of domestic and wild
cloven-hoofed animals [1, 2]. It is known to cause sub-
stantial economic losses, directly from the effect of the
virus on animal health and indirectly through control
efforts including quarantines and trade restrictions [2].
The disease is caused by infection with a single
stranded, positive sense, RNA virus (FMDV) belonging
to the genus Aphthovirus within the family Picornaviridae.
This virus occurs in seven distinct serotypes namely: O, A,
C, Asia 1, SAT 1, SAT 2 and SAT 3, each having multiple
strains [3, 4]. All serotypes, except Asia 1, have been
reported in eastern Africa, however, serotype C was last de-
tected in Kenya in 2004 and may be extinct [5, 6]. Sero-
types O and A are considered endemic in most parts of
Africa, while the three SAT serotypes have usually been re-
stricted to sub-Saharan Africa [7], where they are com-
monly diagnosed [7–9]. However, incursions of SAT 1 into
the Middle East (1961–1965 & 1970), and SAT 2 into
Saudi Arabia (2000), Libya (2003) and more recently into
Egypt and Libya (2012) have been reported [7, 10].
The maintenance of the three FMDV SAT serotypes in
cattle in southern and eastern Africa has been associated
with contact with wildlife, especially African buffalo
(Syncerus caffer) [11]. FMDV has been demonstrated to
persist in individual buffalo for up to 4–5 years and in
isolated buffalo herds for up to 24 years [11]. In southern
Africa, it has, in some cases, been concluded that buffalo
have been the source of FMDV infections in cattle and
impala (Aepyceros melampus) [8, 12, 13]. As a result,
FMD control policies in southern Africa are centred on
isolating the buffalo, in the National Parks and game re-
serves, away from the surrounding livestock populations,
and vaccinating cattle kept in buffer zones around these
areas against the FMDV serotypes that are carried by the
nearby buffalo [14].
In eastern Africa, FMD was first reported in cattle in
1932 [15] and since then, the marketability of livestock
and animal products within, and outside, the region has
been negatively affected [16]. The maintenance of
FMDV in the region has been attributed to various fac-
tors including: the presence of numerous wildlife reser-
voirs [7, 17–19], communal and pastoral grazing systems
that enable contact between livestock and wildlife [20],
poor diagnostic capacity in the region [9], emergence of
new strains [21–23], transboundary animal movements
and traditional cultural practices such as the exchange
of live animals for dowry and gifts [24, 25]. East African
countries have tried to control the disease mainly by
quarantine and post outbreak vaccination. However,
these measures have been difficult to enforce and sub-
optimal use of vaccines [26] has resulted in large parts
of the FMDV susceptible animal populations remaining
at risk [9, 27]. Recently, the countries in this region have
established a network to combine their control efforts to
move towards freedom from FMD by 2020 following the
progressive control pathway (PCP) for FMD as described
[28]. The PCP defines six steps in the process of achiev-
ing freedom from FMD including effective monitoring
of circulating serotypes, vaccination and improved biose-
curity measures [28]; this strategy has been adopted by
all countries in the region, including Uganda [29].
In Uganda, SAT 1 FMDV was first reported in 1959,
and since then, FMD outbreaks caused by serotypes O,
A, SAT 1 and SAT 2 [7, 9, 24, 27, 30–33] have been
regularly reported in livestock. In addition, for the first
time, serotype SAT 3 FMDV has been recently isolated
from a clinically healthy long horned Ankole calf shortly
after its introduction into the area close to the Queen
Elizabeth National Park (QENP) [34]. Ugandan buffalo are
only infrequently sampled for FMDV, and thus the virus
has only been isolated from them during two studies in
QENP; these yielded serotypes SAT 1 and SAT 3 in 1997
[35] and SAT 1 and SAT 2 in 2007 [36]. Moreover, in a
post-outbreak study conducted on adult cattle and goats
in the same area, concurrently with the 2007 buffalo sam-
pling, only serotype O FMDV was isolated. Furthermore,
11 herds of cattle had animals with higher antibody titres
against serotype O than against the SAT serotypes, while
only one had convincing serological evidence of infection
with SAT FMDV [22, 31]. Thus, although wildlife within
the Ugandan National Parks are often blamed for being
the source of FMD outbreaks in their surroundings [37],
this could not be proven for the major 2006 FMD
outbreak in the QENP area [31, 36]. Moreover, although it
is clear that FMDV can pass from buffalo to cattle [13],
recent attempts in Uganda and Kenya to establish the
role of the African buffalo in the epidemiology of
FMD in domestic species in eastern Africa have so far not
settled this [36, 38].
The objective of this study was to assess the presence
of FMDV in young, unvaccinated cattle grazing in close
proximity to African buffalo in the QENP (Fig. 1)
and to establish whether these buffalo play a major
role in the maintenance of FMD in livestock around
the National Park.
Methods
This study was designed in compliance with REFLECT
guidelines and was approved by the Ugandan Ministry
of Agriculture, Animal Industries and Fisheries (MAAIF)
(Reference LHE 199/01, Uganda) and Makerere University
(MU) “School Higher Degrees and Research Committee”.
The sampling was carried out by MAAIFs National
Animal Disease Diagnostics and Epidemiology Centre
(NADDEC) in collaboration with Kasese District Veterinary
Office in accordance to the guidelines from MAAIF. The
Dhikusooka et al. BMC Veterinary Research  (2016) 12:5 Page 2 of 13
study included meetings for the herd owners where the
purpose of the project was described and informed
consent to the sampling, and to participation in the
questionnaire survey, was obtained from the individual
herd owners.
Sampling approach
A cross-sectional study was conducted in Katwe Kabatooro
and Nyakatonzi subcounties of Kasese district in Uganda
(Fig. 1) during August-September 2011 to assess the
presence of FMDV and antibodies against this virus.
The sampled herds were usually grazed communally
close to (and inside) the QENP, where the animals, ac-
cording to the herd owners, regularly moved/grazed/drank
within 2–10 m of wildlife. FMD was last reported from
this area in 2006–2007, and no vaccinations against
FMDV had been carried out in this area since 2007.
The two sampled subcounties had an estimated cattle
population of 30,000 head of cattle distributed in ap-
proximately 50 herds (personal communication, DVO
Dr. V. Kalule, based on [39]). Moreover, it was estimated
that approximately 1/6 of these, i.e. 5,000, were unvac-
cinated 6-24-month-old cattle. A sample size of 296 was
calculated using Win Episcope 2.0 software [40] at a 5 %
precision level and 95 % confidence level and assuming
antibody prevalence of approximately 12 % [41].
At the sampling, both unstabilised blood and oropha-
ryngeal fluid (OP) samples were collected from each of
247 heads of 6-24-month-old cattle. The cattle belonged
to 24 settled pastoralists, who in total owned 1171 cattle
Fig. 1 Map of the study area: Queen Elizabeth National Park (QENP) and its surroundings. Generated using QGIS, version 2.6.1
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within this age-cohort, and in each herd, sampled animals
were randomly selected. Due to the field conditions, the
calculated number of samples was not entirely met;
however, the number of cattle in the sampled age-group
in the 24 sampled herds was also lower than estimated
(2400), so this was evaluated as adequate.
The OP samples were immediately divided into two
aliquots: one placed in phosphate buffered saline (PBS)
and another in RLT buffer (Qiagen, Hilden, Germany)
and kept in liquid nitrogen until stored at −80 °C in the
laboratory, while serum was extracted in the field and
kept on ice until stored at −20 °C in the laboratory.
Information on: vaccination history, laboratory con-
firmed FMD outbreaks, unreported observation of clin-
ical symptoms of FMD, farming characteristics, history
of contact between cattle and wildlife, age group mostly
affected in the event of FMD outbreaks and FMD con-
trol methods was collected from the herd owners using
a semi-structured questionnaire (Additional file 1).
Serology
Sera were screened for the presence of antibodies against
FMDV NSPs using PrioCHECK® FMDV NS ELISA test
kits (Prionics, Lelystad, The Netherlands) according to
the manufacturer’s instructions. Positive samples were
tested (at 1:10 dilution) for antibodies against the seven
different FMDV serotypes using solid phase blocking
ELISAs (SPBEs) [42]. Results were read as the optical
density (OD) of wells with test samples and expressed as a
percentage of the mean optical density (ODP) of four wells
with a known negative control serum. Sera were consid-
ered positive, if the ODP was < 50 % for serotypes O, SAT
1, SAT 2 and SAT 3, < 45 % for serotype A, and < 35 % for
serotypes C and Asia 1. Due to expected cross-reactions,
all sera giving positive reactions in the initial screening
were titrated in two-fold dilution series from 1/10 to
1/1280 and titres expressed as the reciprocal of the
highest positive dilution [42]. Nineteen samples with ti-
tres ≥ 80 in the SPBEs were tested in the relevant virus
neutralization tests (VNTs) as described in the OIE Manual
[43], while twelve sera with SPBE titres ≤ 40 were not tested
further. FMDV strains used for VNT comprised O Manisa,
A Iraq 24/64, C Noville, Asia 1 Shamir, SAT 1 BOT/68,
SAT 2 ZIM 5/81 and SAT 3 ZIM 4/81; VNT titres ≥ 45
were considered positive, titres of 15–44 inconclusive and
titres ≤ 14 negative.
Detection of FMDV RNA and isolation of FMDV from OPs
Thirty two OP samples collected from the animals with
antibodies against FMDV NSP were initially screened for
FMDV RNA using the 5'-untranslated region (UTR) tar-
geted quantitative reverse transcription PCR (RT-qPCRs)
[43, 44] and 22 of these with threshold cycle values
(CT values) ≤ 39 were inoculated onto primary bovine
thyroid cells (BTY) and propagated through two cell
culture passages [32, 36, 43]. Cultures with cytopathic
effect (CPE) were harvested and stored at −80 °C. The 3D
coding region targeted RT-qPCR assay was then performed
on RNA extracted from the cell harvests as described pre-
viously [45] and samples with CT < 32 were interpreted as
FMDV RNA positive while CT values ≥ 32 were considered
negative [45, 46]. The presence of FMDV in CPE-positive
harvests was analysed using an in-house antigen ELISA,
which also determined the serotype of positive isolates as
previously described [32, 36, 43].
Sequencing of VP1 coding region from FMDV isolates
RNA was extracted from FMDV antigen positive cell
culture harvests as described above, and cDNA synthe-
sized using Ready-To-Go You-Prime First-strand Beads
(GE Healthcare Life Sciences, Uppsala, Sweden) with ran-
dom hexamer primers (pd(N)6) [27]. The cDNA was di-
luted to 150 μl from which an aliquot was used for VP1
coding region amplification as follows: 5 μl 10X PCR buf-
fer, 4 μl 25 mM MgCl2, 25.1 μl dH2O, 0.5 μl Amplitaq
Gold® DNA Polymerase (Applied Biosystems Foster City,
USA), 0.4 μl 10 mM dNTPs, 5.0 μl of each of forward
(13 KPN-100 [5´GGGTGGBBGTSTWMCAGRTSACM-
GACAC 3´]) and reverse (FMD KS2B58 [5´-ACAGCGGC
CATGCACGACAG 3´] primers, where B = (C or G or T);
S = (C or T); W= (A or T); M = (A or C) and R = (A or G)
[47], with 5 μl of cDNA [36, 48].
The PCR was run in a thermocycler (Gene Amp-PCR
system 3700 version 3.0 Applied Biosystems) using the
touchdown technique as described [48]. The PCR prod-
ucts (731 bp) were purified using QIAquick® gel extrac-
tion and purification kit (Qiagen, Hilden, Germany), and
quantified using a Nanodrop®1000 spectrophotometer
(Fisher Scientific, Waltham, MA, USA). Sequencing of
the PCR products was performed using a BigDye®
Terminator v 3.1 Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA, USA), using the same primers
as used in the PCRs, according to the manufacturer’s
instructions, and ran on an automated DNA sequencer
(ABI PRISM® 3730 DNA Analyser (Applied Biosystems,
Foster City, CA, USA).
Sequence assembly and analysis
Nucleotide sequences were assembled and edited using
SeqMan Pro™ software (DNAStar Lasergene 10.0, Madi-
son, WI, USA). The resulting consensus sequences were
compared to others using the Basic Local Alignment
Search Tool (BLAST) in MEGA 5 (www.megasoftware.net
[49]). They were then aligned with 19 other published nu-
cleotide sequences obtained from GenBank (Table 1) in
MUSCLE incorporated in MEGA software version 6.06,
and trimmed to correspond to the 657 nt encompassing
the complete VP1 coding region. Phylogenetic trees were
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estimated using the Neighbor Joining (NJ) method [50],
with 1000 bootstrap replicate samplings and used to
determine the topotype clusters for the aligned se-
quences. The amino acid sequences were deduced from
the nucleotide sequences using the standard genetic
code and the extent of amino acid relatedness in the
VP1 coding regions determined using the same program
in MEGA 6 [51].
Results
Clinical signs of FMD were not observed in any of the
sampled animals or herds.
Serology
In total, 37 of 247 sera collected from 24 herds in
Nyakatonzi and Katwe Kabatooro subcounties tested posi-
tive for antibodies against the NSPs of FMDV (Table 2)
giving an overall antibody prevalence of 15 % with herd
antibody prevalences ranging from 0 to 60 % (median
11 %; Inter Quartile Range (IQR) 0–26 %). In the 14 posi-
tive herds, the antibody prevalences in the NSP antibody
test ranged from 6 to 60 % (median 23 %; IQR 16–30 %).
Screening of the 37 anti-NSP antibody positive samples
in SPBEs resulted in 17, 4, 2, 0, 20, 13 and 16 samples
being scored positive for antibodies against serotypes O,
A, C, Asia 1, SAT 1, SAT 2 and SAT 3, respectively, while
12 anti-NSP positive samples were negative in all SPBEs
(Table 2; data not shown for the testing of antibodies
against serotypes A, C and Asia 1). When titrated, the few
sera that were identified as positive for antibodies against
serotypes A and C in the initial screening (at 1:10 dilution)
had titres ≤ 40 and so were considered negative. In con-
trast, titres ≥ 80 were found in 5/17, 6/20, 4/13 and 3/16
of the samples titrated for antibodies against serotypes O,
SAT 1, SAT 2 and SAT 3, respectively (Table 2). In
summary, the positive results were obtained from 11
sera collected from 6 different herds. Six of these sera
had high antibody titres against one single serotype
(O: 1 sample; SAT 1: 2 samples; SAT 2: 2 samples,
SAT 3: 1 sample), whereas five sera had high antibody
titres against more than one of the serotypes O, SAT 1,
SAT 2 and SAT 3 (Table 2).
Neutralising antibodies (as determined by VNT) were
only detected against serotype O and only in three ani-
mals, while eight, six, five and six sera had inconclusive
neutralizing antibody titres against O, SAT 1, SAT 2 or
SAT 3, respectively, and all the other tested sera were
negative (Table 2). The three VNT positive animals had
SPBE antibody titres ≥ 160 and came from three different
herds (H1, H14 and H19).
Diagnostic RT-qPCRs, virus isolation and antigen ELISA
In the 5´UTR RT-qPCR assay, 22 out of the 32 tested
OP samples generated CT values ranging from 22 to 39,
Table 1 SAT 1 VP1 coding sequences included in this study
Species Isolate Identity GeneBank accession no. Year of sampling Country Topotype
Cattle UGA/116/13** KP025678 2013 Uganda IV (EA-1)
Cattle UGA/161/13** KP025679 2013 Uganda IV (EA-1)
Buffalo UGA/10/70 KF219681 1970 Uganda IV (EA-1)
Buffalo UGA/21/70 KF219682 1970 Uganda IV (EA-1)
Buffalo UGA/1/97 AY442012 1997 Uganda VIII (EA-3)
Unknown UGA/7/99 AY442011 1999 Uganda IV (EA-1)
Buffalo UGA/1/07 HM067706 2007 Uganda IV (EA-1)
Cattle UGA/13/74 AY442010 1974 Uganda VII (EA-2)
Cattle ETH/19/07 FJ98156 2007 Ethiopia IX
Cattle ETH/21/07 FJ798157 2007 Ethiopia IX
Cattle KEN/11/91 AY441994 1991 Kenya I (NWZ)
Cattle KEN/9/91 AY441995 1998 Kenya I (NWZ)
Cattle KEN/28/06 HQ267529 2006 Kenya III (WZ)
Cattle KEN/66/80 HQ267520 1980 Kenya I (NWZ)
Cattle TAN/2/77 AY442008 1977 Tanzania I (NWZ)
Cattle TAN/155/71 (Vaccine) HQ267519 1971 Tanzania I (NWZ)
Cattle TAN/19/96 AY442005 1996 Tanzania I (NWZ)
Cattle TAN/60/99 AY442002 1999 Tanzania III (WZ)
Cattle NIG/2/79 AF431728 1979 Nigeria VI
Cattle KNP/196/91 DQ009716 1991 South Africa II (SEZ)
**: sequences obtained as part of this study
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Table 2 Summarized results from herds with animals positive for antibodies against FMDV NSPs
Subcounties Parishes Herd
no.
NSP ELISA
Pos/tested (%)
SPBE titre VNT titre Serological
conclusion
herd-level
Cell culture
BTY
Antigen ELISA
on BTY harvest
3D RT - qPCR (CT)
on virus harvests
Herd
diagnosis*
O SAT 1 SAT 2 SAT 3 O SAT 1 SAT 2 SAT 3
Katwe Rwenjubu H1 6/23 (26) - 10 - - - - - O +
Kabatooro 640 320 10 40 67 - 28 CPE - -
160 - - - 24 - - - -
10 20 - - -
- 10 - - 17
- 10 - - -
Kijarukara H3 3/12 (25) 10 320 10 40 - 28 - - (SAT 1) - (+)
- - - - -
- - 10 10 CPE - -
Kiganda H7 3/5 (60) - - - - - +
10 - - 10 40 - 17 -
10 10 - 10 34 - 28 -
Top hill H19 4/7 (57) 10 P** - 10 - 24 O +
160 20 10 80 136 - 28 - (SAT 2) CPE - 32
- - 80 10 - - 40
10 20 - 80 24 - 28 -
Kyakitare H18 2/10 (20) 10 80 10 10 - 34 28 (SAT 1) CPE SAT 1 16 ++
10 40 40 20 - - CPE SAT 1 19
Kiganda H2 1/7 (14) - - - - - (+)
Rwenjubu H5 2/7 (29) - 10 10 10 17 - (+)
- - - -
Nyakatonzi Muruti H12 5/18 (28) - - - (+)
- - - -
- - - -
- - - -
- - - -
Muruti H15 3/9 (33) - - - - - (+)
- 10 - - - 17 - -
40 - - - - - - -
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Table 2 Summarized results from herds with animals positive for antibodies against FMDV NSPs (Continued)
Muruti H14 1/5 (20) 160 160 80 20 48 24 - - O CPE - 32 +
Kisasa H23 4/25 (16) 160 80 20 320 24 - - 17 (O) CPE - 32 +
- 160 160 - - - 28 (SAT 2) CPE - -
40 40 40 - 40 - - -
20 20 80 40 40 - - CPE - -
Kisasa H22 1/6 (17) 10 20 - 10 34 - - 28 CPE - - (+)
Kisasa H21 1/17 (6) - - - - (+)
Bwanika H11 1/13 (8) - - - - - (+)
No. Positive 37/247 (15) 17 20 13 16 3 0 0 0 na 2
No. with SPBE-
titre≥ 80
5 6 4 3
-: Negative
*: (+) only few animals with antibodies against the NSPs
+ Herds with more substantial evidence of exposure to FMDV
++ Confirmed evidence of exposure to FMDV
**: Positive in SPBE 1:10 but not titrated due to insufficient sample
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of which only three samples had CT <32 (22, 23 and 25).
Ten of these 22 OP samples produced CPE when inocu-
lated onto primary BTYcells but only two cell culture
harvests (UGA/116/13 and UGA/161/13) were found
positive in the 3D RT-qPCR assay (defined as positive:
CT < 32) and these had CT values of 16 and 19 (indica-
tive of high levels of FMDV RNA). Moreover, only the
same two virus harvests were found positive for FMDV
antigen in FMDV antigen ELISAs and were identified as
serotype SAT 1 (Table 2). These two virus harvests were
generated from the OP samples with the lowest CT
values in the 5´UTR RT-qPCR assay, and were both col-
lected from herd H18. RNA extracted from cell harvests
derived from one OP from each of herds H14, H19 and
H23 each had a CT value 32 in the 3D RT-qPCR, which
is on the borderline of confidence in detection [46], but
no FMDV could be isolated.
Herd diagnosis
There was no evidence of exposure to FMDV in ten of
the 24 herds in this study (H4, H6, H8, H9, H10, H13,
H16, H17, H20 and H24) (data not shown), while four
herds had antibodies against FMDV NSPs only, either in
one animal (H2, H11 and H21) or in five animals (H12)
(Table 2). Another four herds had anti-NSP antibody
seroprevalences of 17–33 % (1–3 animals) with anti-
bodies against one or more serotypes in 1–2 of these an-
imals (H3, H5, H15 and H22). Six herds had more
substantial evidence for exposure to FMDV. This was in
the form of higher seroprevalences (43–60 %) of anti-
bodies against FMDV NSPs (H7 and H19), SPBE anti-
body titres ≥ 80 in more than one animal (H1, H19 and
H23), neutralising antibodies in one animal (H1, H14
and H19) and isolation of FMDV from OPs (H18).
Characterisation of FMDV isolates
Sequencing revealed that the two 657 nucleotide (nt)
long regions, from the 731 bp amplicons, corresponding
to the VP1 coding sequences of UGA/116/13 and UGA/
161/13 were identical. Alignment of these complete VP1
sequences with 18 other African FMDV isolates (Table 1)
showed that they belonged to the SAT 1 topotype IV
(EA-1) (see Tekleghiorghis et al. [52]), clustered together
with three previous Ugandan buffalo isolates of 1970
and 2007 (UGA10/70, UGA/21/70 and UGA/1/07) and
also the UGA/7/99 isolate whose species of origin was
not identified (Fig. 2). The VP1 sequences of the 2013
isolates had 21 %, 20 % and 24 % nucleotide (nt) differ-
ence from these earlier buffalo isolate VP1 sequences,
respectively, while their relationship with another Ugan-
dan buffalo isolate from 1997 (UGA/1/97) and an earlier
Ugandan SAT 1 cattle isolate (UGA/13/74) was even
more distant (nt sequence divergences of 30 % and 31 %,
respectively). However, except for the UGA/13/74 strain
[topotype VII (EA-2)] and UGA/1/97 [topotype VIII
(EA-3)], the various Ugandan isolates represent inde-
pendent lineages within topotype IV (EA-1) (Fig. 2). The
SAT 1 vaccine strain (TAN/155/71) used in Uganda be-
longs to a different topotype I (NWZ) and differs from
the SAT 1 VP1 sequences obtained from this study by
26 % and 21 % at the nucleotide and amino acid level,
respectively.
Since the VP1 sequences of the two isolates from
H18 were identical, the 20 aligned SAT 1 VP1 coding
sequences (Table 1) encoded 19 different amino acid
sequences, each with 219 amino acid residues (Fig. 3),
which were conserved at 51.3 % of the sites. Multiple
amino acid substitutions were observed within the
known hypervariable regions [53]. In the G-H loop, com-
pared to the vaccine strain (TAN/155/71), residues 137
and 149–151 (the receptor binding RGD motif) remained
conserved in all the 19 sequences, while multiple substitu-
tions occurred in the section including residues 138–148
which is known to be a key antigenic region in FMDVs
[53]. The seven Ugandan isolates were conserved at resi-
dues 146, 152 and 153 with each having a distinct amino
acid (aa) substitution at positions 140–143. UGA/116/13
showed full aa conservation with UGA/7/99, UGA/1/07,
UGA/13/74 and UGA/21/70 at positions 138, 139,
144 and 145, while the UGA/1/97 and UGA 10/70
strains had different substitutions (Fig. 3). UGA/116/13
had multiple substitutions at positions 140(N→A),
141(H→D), 142(E→Q), 143(T→A), 147(H→N) and
148(I→V) compared to the vaccine strain (TAN/155/71)
and distinct substitutions in these positions were also
observed in the other Ugandan isolates but without a
pattern. In the H-I loop (residues 172–182), all the 19 se-
quences were fully conserved at positions 172, 176 and
181–182. However, there were distinct substitutions
among the Ugandan isolates within this region. Near the
C-terminus (residues 203–219), five positions (203, 208,
216, 218 and 219) were conserved in all the 19 isolates,
while the Ugandan isolates also showed full conservation
at positions 209, 210 and 213 plus almost complete con-
servation at positions 207, 211 and 217 (Fig. 3). The
UGA/116/13 differed from the other 6 strains by having
substitutions outside the G-H loop (139–153), the H-I
loop (172–182) and the C-terminus (203–219) (see Fig. 3).
Herd owner replies to semi-structured questionnaires
According to the responses to questionnaires (see
Additional file 1), 96 % of the herd owners grazed their
herds communally inside QENP and 63 % frequently ob-
served close contact with buffalo, especially during the dry
season. Moreover, 75 % of the farmers reported that buf-
falo and other wildlife grazed around the cattle kraals dur-
ing the night. Most farmers were aware of FMD outbreaks
in their area, 58 % had experienced clinical FMD in their
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herds and 12.5 % had observed signs similar to clinical
FMD (although not confirmed) since the last documented
outbreak in 2006 (see Additional file 1). When suspected
cases of FMD occurred, 63 % of the farmers reported this
to the area veterinarian, 17 % drove the animals into the
waters of the Albertine rift valley salt lakes, 33 % applied
local herbs and 4 % treated with oxy-tetracycline sprays.
Discussion
At the QENP livestock-wildlife interface, young unvaccin-
ated cattle from 24 herds without reports of clinical signs
of FMD had an overall seroprevalence of 15 % (37/247)
for antibodies against FMDV NSPs. This is higher than
the 5 % seroprevalence reported in cattle herds without
clinical signs in the same area in 2006 [31] but compares
well with the 12 % value reported in young calves in
FMD-endemic Ethiopia [41].
Evidence for prior FMDV infection varied between
herds, thus evidence for exposure to FMDV was absent in
ten herds, scanty in eight herds and more substantial in
six herds (25 %). The observed scattered presence of
antibodies does not appear to fit well with the general ap-
preciation of the epidemiology of FMD as an efficiently
spreading disease with high morbidity in affected herds
and high risk of transfer to other herds through physical
contact and fomites [54]. Moreover, although the farmers
were well acquainted with clinical signs of FMD, a number
of them would not report outbreaks, but rather used
traditional control measures like application of local herbs
or walking the animals through the salt lakes known to
contain common salt and sodium bicarbonate [55].
There is an undefined level of trade with cattle, includ-
ing young stock for fattening, coming into the area from
other districts; thus individual animals with antibodies
against FMDV may be explained as animals infected
elsewhere and brought into the herds as replacement
stock or gifts to the owners as part of local customs
[32]. However, the higher antibody prevalences in H7
and H19 and the isolation of SAT 1 FMDV from OPs
from two cattle in H18 support spread within these
herds (originating either from within the district or from
other districts); moreover, it cannot be excluded that the
Fig. 2 A Neighbor-joining tree showing the relationships between the VP1 coding sequences (657 nt) of the two Ugandan SAT 1 isolates from this study
(UGA/116/13 [KPO25678] and 161/13 [KPO 25679] (marked **)) and SAT 1 FMDV VP1 coding sequences from Uganda (UGA), Kenya (KEN), Tanzania (TAN),
Ethiopia (ETH), Nigeria (NIG) and Kruger National Park (KNP) in South Africa as obtained from GenBank (http://www.ncbi.nlm.nih.gov/genbank/).
Topotypes are indicated according to Tekleghiorghis et al. (2014) [49]. Bootstrap values are indicated. Scale bar indicates nucleotide
substitutions per site
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infections causing antibodies in the other herds have
taken place in Kasese district.
Another possibility is that some of the antibodies
against FMDV observed in this study are residual mater-
nally transferred antibodies. Since cattle in this area are
likely to have their first calf at 3–4 years of age and to
have several calves, it is likely that some of the dams to
the sampled calf cohort (born between August 2009 and
February 2011) were exposed to FMDV by infection
and/or vaccination during the 2006–2007 outbreak
[31, 56]. A fraction of these dams may have retained suffi-
cient level of antibodies, especially against the NSPs, to
transfer these to their offspring. Moreover, although FMD
outbreaks had not been reported in the area since 2006,
the District Veterinary Office noted that underreporting
was suspected since quarantine restrictions due to FMD
would paralyze all economic activities in the area.
Although it is not clear when, or how, some of the
antibody positive animals in these herds were infected,
SPBE assays showed that 11 of the 37 NSP positive sam-
ples had antibody titres ≥ 80 against one or more sero-
types. Based on SPBE and VNT results from the few
positive animals, it appeared that serotype O FMDV had
infected some animals from H1, H14 and H19, while
SAT 1 FMDV had infected some animals from H3 and
possibly H18, in the latter case this was confirmed by
isolation of SAT 1 FMDV from two animals. The situation
was unclear in herds H19 and H23 with high SPBE anti-
body titres against serotypes O, SAT 1, SAT 2 and SAT 3,
which could be due to the previously observed cross-
reactivity between the SPBEs and also between the VNTs
[31, 56]. Moreover, if animals were purchased from other
districts, vaccine-derived antibodies cannot be excluded ei-
ther. In accordance with previous findings in the area [31,
56], there was no conclusive serological evidence for previ-
ous infection by serotypes A, C, Asia 1 and SAT 3 in the
sampled cattle, although very recently SAT 3 FMDV was
isolated from an asymptomatic calf from the area [34].
The SAT 1 FMDV isolates obtained from the two
healthy animals in H18 are the first reported SAT 1 iso-
lates from Ugandan cattle since 1999 [57], while SAT 1
isolates have been obtained from buffalo in QENP in
1997 and 2007 [35, 36]. The relatively infrequent isola-
tion of SAT 1 FMDV from outbreaks in Ugandan cattle
could be the result of poor surveillance in the form of
underreporting of FMD outbreaks and limited submis-
sion of samples of sufficient quality for virus isolation to
the central diagnostic laboratory at the National Animal
Disease Diagnostics and Epidemiology Centre (NADDEC)
(Dr. Anna Rose Ademun, personal communication). More-
over, there have been limited options for typing FMDV
locally in Uganda [9].
Fig. 3 The sequence alignment for the VP1 protein of 19 SAT 1 FMD viruses. Dots indicate amino acid residues identical to the reference
sequence SAT 1 TAN/155/71
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The combination of rather low CT values (22 and 23)
in the 5'UTR tests for the two H18 OP samples that
yielded the SAT 1 FMDV isolates and SPBE antibody ti-
tres of 40 and 80 for antibodies against SAT 1 FMDV in
sera from the same animals, indicate that these two ani-
mals were in the subacute stage of the infection. How-
ever, no clinical signs were observed during the
sampling and there were no reports of clinical signs in
this or in other cattle herds in the area. Moreover, the
questionnaire responses indicated that the indigenous
Ankole cattle from this area have less severe clinical
signs of FMD than the pure exotic and crossbred cattle.
Hence, these data support the notion that some of the
Ugandan indigenous Long-horned Ankole cattle may go
through FMDV infection with only minimal clinical
signs of FMD. This is consistent with the very recent
isolation of SAT 3 FMDV from an OP sample from a
clinically healthy young calf in the QENP area [34] and
has been previously reported for indigenous cattle in
Botswana [58, 59]. If true, this notion has a bearing on
the passive surveillance reporting system for FMD in
Uganda that is based on clinical observations.
This study shows a considerable genetic difference be-
tween the current Ugandan SAT 1 cattle virus and the
vaccine strain (TAN/155/71) that is currently used to
control FMD outbreaks caused by SAT 1 FMDV in
Uganda, indeed these belong to different topotypes.
Thus, vaccine matching studies using the currently
circulating SAT 1 strain are required. In addition, the
observed differences from earlier buffalo and cattle
isolates imply that different SAT 1 lineages have been
in circulation in this area over the last 50 years. To
verify this, more Ugandan FMDV SAT 1 isolates
should be collected and characterised.
Despite the close interaction that occurs between cat-
tle and buffalo at the QENP livestock-wildlife-interface,
this study did not provide evidence to support the view
that the FMD viruses circulating in cattle in this area
originate from wildlife as has been observed in South
Africa [60]. This could be attributed to the limited num-
bers of isolates from cattle and the long time-intervals
between their isolations; but it also does not exclude the
possibility that separate pools of viruses circulate in
cattle and wildlife. The VP1 coding sequences of five
of the six Ugandan SAT 1 isolates were different from
those of isolates from other countries, indicating that
the Ugandan SAT 1 strains may be geographically
limited to Uganda as previously suggested [61].
Conclusions
Although FMD was last reported in Kasese District in
2006, evidence of infection with FMDV was found in six
of 24 cattle herds from the QENP livestock-wildlife-
interface. The SAT 1 FMDV isolated from one of these
six herds was markedly different from the earlier buffalo
isolates from the same area; thus transmission between
buffalo and cattle could not be proven. The genetic differ-
ence (ca. 26 % within the VP1 coding region) between the
current SAT 1 isolates and the vaccine strain used to con-
trol FMD outbreaks in the country calls for vaccine match-
ing to ensure the effectiveness of vaccination in this region.
Additional surveillance and characterization of field strains
from cattle and buffalo at this livestock-wildlife interface is
necessary for monitoring of emerging strains and to en-
hance the understanding of the role of wildlife in the epi-
demiology of FMD in cattle in East Africa.
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